TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
EDIT

Editas Medicine Inc

Healthcare · Biotechnology · listed since 2016

2.70$ +0.4% vs. previous close Closing price · As of: Sep 17, 2026
🔔 Watch stock
Add to watchlist

Assessment

Our Rating

A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.

Open questions

The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.

Why this colour

Yellow, and only just: on the latest evidence none of the hard substance findings that trigger a red light here are present. No filing carries a going concern warning; on May 5, 2026 Editas expressly stated that its funds would last at least twelve months. Equity was almost gone at $4.4 million on March 31, 2026 — but positive, and the May 26, 2026 offering lifted it to a pro forma $121.4 million. Against roughly $241 million of pro forma cash and $23.1 million of operating cash burn in the latest quarter, that reaches well beyond four quarters; there is no callable bank loan, no interest or repayment date that could topple the company, and no listing deadline. What is open is precisely the question everything rests on: since its founding in 2013 not one dollar of product revenue has been booked, $1.65 billion has been consumed, the best in-house program was discontinued on December 11, 2024, and the only recurring cash stream — the Vertex license fees — has been sold to DRI up to 100 percent and now repays debt instead of becoming income. On top of that, the decisive Cas9 patents do not belong to Editas but are in-licensed from Broad and Harvard. What remains is a single preclinical molecule whose first human data Editas itself expects by the end of 2026. A company whose outcome hangs on one readout carries no substance risk in the sense of our traffic light, but no proven quality either — hence yellow. If that readout slips or disappoints, this rating belongs back on the bench. The decision is yours.

What the thesis turns on

Assessment: Opportunities & Risks

Editas Medicine is the pioneer trap in pure form: a co-founder of the CRISPR era whose patents are good enough that Vertex and Bristol Myers Squibb pay for them — yet which, after $1.65 billion of accumulated deficit, has never earned a dollar of product revenue. Its own best program was discontinued on December 11, 2024, 65 percent of the workforce was let go, and the recurring license stream was sold to a royalty investor. Equity was down to $4.4 million on March 31, 2026; the May 26, 2026 offering brought roughly $117.0 million and more than 56 percent additional shares. What remains is a well-funded, extremely concentrated bet on a single preclinical molecule. Not investment advice.

Business model & product maturity

By its own statement in the quarterly report (10-Q) for the period ended March 31, 2026, Editas has never generated any product revenue; the annual report (10-K) for 2025 places every program at the preclinical or research stage. The most advanced program, reni-cel, was discontinued on December 11, 2024 — moving the company back from clinical to preclinical status.

Revenue source & dependency

The $40.5 million of 2025 revenue consists of collaboration and license income; the $78.1 million peak in 2023 was essentially the $50.0 million Vertex upfront payment. The recurring Vertex fees were sold to DRI Healthcare in October 2024 (up to 100 percent, $57.0 million upfront): they still run through revenue — $10.0 million of annual license fee in fiscal 2025 — but the cash repays the $54.7 million liability (March 31, 2026).

Cost discipline

The cost program is complete and working: research and development at $90.0 million (2025) after $199.2 million (2024), administration at $49.9 million after $72.0 million, and a quarterly loss of $25.0 million (Q1 2026) after $76.1 million (Q1 2025). The restructuring line stood at zero in the first quarter of 2026 — the $60.7 million rebuild of 2025 is paid for.

Balance sheet & funding

Equity fell from $134.3 million (December 31, 2024) to $27.3 million (December 31, 2025) and $4.4 million (March 31, 2026) against $144.9 million of liabilities. The May 26, 2026 offering brought roughly $117.0 million net but cost more than 56 percent additional shares (97,906,282 to 153,461,838). Company runway estimate: the second half of 2028.

Scientific substance

The patents are solid enough that Vertex pays annual fees of $5.0 million to $40.0 million through 2034 and BMS has built 14 programs on them. For EDIT-401 the company reported on May 14, 2026 a mean LDL cholesterol reduction of 90 percent or greater in non-human primates, durable through roughly six months. Human evidence, however, is entirely absent.

Worth Noting

Editas Medicine reached our research list through the filing calendar of the U.S. securities regulator, the SEC: the current report (8-K) of May 26, 2026 announcing a sale of 55,555,556 shares against roughly 97.9 million then outstanding. We additionally reviewed the annual report (10-K) for 2025, the quarterly report (10-Q) for the period ended March 31, 2026 and every SEC filing through July 29, 2026.

Every figure carries its own reporting date. The shortest-lived are equity ($4.4 million at March 31, 2026), cash ($123.6 million at March 31, 2026) and share count (153,461,838 after May 27, 2026) — all of which move with each quarterly report and each further capital measure.

The market value of roughly $402 million is the calculation 153,461,838 shares times a $2.62 closing price as of the July 28, 2026 data cut-off, and it moves with every trading day. The cross-check is the last price Editas itself recorded in an SEC document (prospectus supplement of May 26, 2026, price of May 22, 2026: $2.76, or roughly $424 million) — the gap of a good five percent confirms the order of magnitude. Do not confuse the parties: CASGEVY belongs to Vertex Pharmaceuticals, not to Editas, which holds only a license position in it.

Stock Watch

This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at EDIT since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 1.70 $ to 4.20 $ · Last price: 2.70 $ (As of: September 17, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.4$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 154m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.2%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 2.1

Performance

Perf. 1M ?Price performance over the last month. -8.10%
Perf. 3M ?Price performance over the last 3 months. -9.30%
Perf. 6M ?Price performance over the last 6 months. 27.20%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 27.80%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -36.9%
Perf. 1Y ?Price performance over the last 12 months. 0.00%
Perf. 3Y ?Price performance over the last 3 years. -67.58%
Perf. 5Y ?Price performance over the last 5 years. -95.70%
Perf. 10Y ?Price performance over the last 10 years. -81.23%
Perf. Since Inception ?Price performance since the first available trading day (02/03/2016) — with a complete history, that is since the IPO. -85.05%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 2.90$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 2.90$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 2.60$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 43.4
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 77.7%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 83.6%

Calculated from the price history · as of 09/18/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
P/B ?Price-to-book ratio: market value relative to book equity. 93.2
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 8.8
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. -1.4
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. -80.7%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -883.2%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. -157.3%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -326.1%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -23.3%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 14.6%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.4
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. warning zone -11.49
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. weak 2 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). -39.20%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 25.39%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. -92.30%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. 44.70%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. 3
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. 54
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. 42
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. C (46 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Biotechnology

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Editas Medicine Inc EDIT 0.4 -1.4 -80.7 -883.2 25.4 0.0
Vertex Pharmaceuticals Inc VRTX 130.6 31.3 24.5 55.0 38.1 9.6 33.4
Regeneron Pharmaceuticals Inc REGN 82.0 19.9 13.1 44.5 20.7 1.0 35.5
Moderna Inc MRNA 62.7 4.6 -66.0 -131.1 -39.2 532.3
argenx NV ARGX 61.9 38.1 34.2 59.1 32.0 89.6 30.9
Revolution Medicines Inc RVMD 40.9 -9.7 -174,708.6 0.0 -100.0 338.3
BeiGene, Ltd. ONC 40.0 63.1 34.1 88.9 19.1 40.2 6.4
Alnylam Pharmaceuticals Inc ALNY 32.6 61.8 28.4 79.7 23.0 65.2 -48.1
Royalty Pharma Plc RPRX 32.5 31.8 19.6 95.8 100.3 5.1 68.6
Median of companies shown 40.9 34.9 19.6 55.0 20.7 9.6 33.4

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2016 · Revenue: 6 $M 2016 · Operating income: -97 $M 2016 · Net income: -97 $M 2017 · Revenue: 14 $M 2017 · Operating income: -120 $M 2017 · Net income: -120 $M 2018 · Revenue: 32 $M 2018 · Operating income: -114 $M 2018 · Net income: -110 $M 2019 · Revenue: 21 $M 2019 · Operating income: -141 $M 2019 · Net income: -134 $M 2020 · Revenue: 91 $M 2020 · Operating income: -135 $M 2020 · Net income: -109 $M 2021 · Revenue: 26 $M 2021 · Operating income: -193 $M 2021 · Net income: -185 $M 2022 · Revenue: 20 $M 2022 · Operating income: -226 $M 2022 · Net income: -204 $M 2023 · Revenue: 78 $M 2023 · Operating income: -169 $M 2023 · Net income: -153 $M 2024 · Revenue: 32 $M 2024 · Operating income: -251 $M 2024 · Net income: -237 $M 2025 · Revenue: 41 $M 2025 · Operating income: -99 $M 2025 · Net income: -160 $M
2016201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 6 -97 -97 -3.02 -50 135 229
2017 14 -120 -120 -2.98 -9 208 373
2018 32 -114 -110 -2.33 -46 236 420
2019 21 -141 -134 -2.68 -41 262 509
2020 91 -135 -109 -1.87 -180 394 573
2021 26 -193 -185 -2.74 -164 554 677
2022 20 -226 -204 -2.98 -177 361 514
2023 78 -169 -153 -2.02 -132 349 499
2024 32 -251 -237 -2.88 -210 134 342
2025 41 -99 -160 -1.80 -165 27 187

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q2 · 0.5 $M Q2 2024: Q3 · 0.1 $M Q3 2024: Q4 · 30.6 $M Q4 2025: Q1 · 4.7 $M Q1 2025: Q2 · 3.6 $M Q2 2025: Q3 · 7.5 $M Q3 2025: Q4 · 24.7 $M Q4 2026: Q1 · 2.8 $M Q1 2026: Q2 · 11.9 $M Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q2 -0.82 -46.40 1 -82.20 -13,178.80 -57 -61
2024: Q3 -0.75 -36.40 0 -98.90 -101,870.50 -53 -56
2024: Q4 -0.55 -139.10 31 -49.00 -148.30 -51 -51
2025: Q1 -0.92 -21.10 5 310.40 -1,633.50 -48 -48
2025: Q2 -0.63 23.20 4 597.50 -1,487.80 -50 -50
2025: Q3 -0.28 62.70 8 12,265.60 -333.00 -31 -31
2025: Q4 -0.06 89.10 25 -19.20 -22.70 -36 -36
2026: Q1 -0.26 71.70 3 -39.20 -882.40 -23 -23
2026: Q2 -0.15 76.20 12 230.60 -152.90 -30 -30

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 6 of our scanner strategies — each hit links to the scanner.

Breakout & Setup

Momentum & Trend

Research

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Hold 1 = Strong buy … 5 = Strong sell
Analyst Ratings 15
Price Target (average) 6.00$
Distance to price 122.2% The price target sits 122.2% above the current price.

Distribution of Recommendations

Strong Buy 4
Buy 1
Hold 8
Sell 2
Strong Sell 0

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -0.83 -0.99 – -0.66 26 53.9% 7
12/31/2027 -0.75 -0.85 – -0.60 19 9.2% 7

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Valuation

What is priced in?

Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Neutral

Negativ-Befund, geprüft am 29.07.2026 gegen die sechs jüngsten SEC-Berichte von Editas Medicine (Geschäftsberichte 10-K für 2025, eingereicht 09.03.2026, und für 2024, eingereicht 05.03.2025, sowie die Quartalsberichte 10-Q zum 31.03.2026, 30.09.2025, 30.06.2025 und 31.03.2025): In keinem der vier Quartalsberichte kommt „artificial intelligence“, „machine learning“, „AI“, „generative“, „neural network“ oder „large language model“ überhaupt vor. In den beiden Geschäftsberichten gibt es genau eine Fundstelle, und sie steht in Item 1A unter dem Cybersicherheits-Risiko: Vertrauliche Daten könnten abfließen, weil Beschäftigte, Lieferanten oder Partner generative KI-Werkzeuge oder öffentliche KI-Plattformen benutzen. Das ist eine unveränderte Standardformulierung zum Datenschutz — der Satz steht 2024 und 2025 nahezu wortgleich da — und kein konkreter Bezug zum eigenen Geschäftsmodell; nach der Vorrang-Regel also kein Beleg für „bedroht“. Umgekehrt belegt kein Filing einen eigenen KI-Einsatz: Editas beschreibt seine Plattform durchgängig molekularbiologisch (CRISPR-Nukleasen Cas9 und AsCas12a, Lipid-Nanopartikel-Zustellung, funktionelle Hochregulierung des LDL-Rezeptors), und beschrieb die Off-Target-Bewertung im Geschäftsbericht für 2024 als Kombination aus In-silico-, biochemischen und zellulären Methoden — Rechenverfahren, aber keine als KI ausgewiesene Technologie. Der Umsatz besteht ausschließlich aus Lizenz- und Kollaborationserlösen (40,5 Mio. US-Dollar 2025), nicht aus KI-Produkten. Damit weder „verkauft“ noch „nutzt“ noch „bedroht“: dokumentierter Negativ-Befund, Kategorie neutral.

View the full file — quotes, sources, reviewed filings
„Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees’, vendors’ or partners’ use of generative artificial intelligence (“AI”) technologies or public AI platforms."

Darüber hinaus könnten sensible Daten abfließen, offengelegt oder preisgegeben werden, weil unsere Beschäftigten, Lieferanten oder Partner generative Werkzeuge künstlicher Intelligenz („KI“) oder öffentliche KI-Plattformen nutzen — oder im Zusammenhang mit einer solchen Nutzung.

10-K · 2026-03-09 · View SEC filing

„Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees’, vendors’ or partners’ use of generative AI technologies."

Darüber hinaus könnten sensible Daten abfließen, offengelegt oder preisgegeben werden, weil unsere Beschäftigten, Lieferanten oder Partner generative KI-Technologien nutzen — oder im Zusammenhang mit einer solchen Nutzung.

10-K · 2025-03-05 · View SEC filing

Filings Reviewed: 10-Q 2026-05-05 · 10-K 2026-03-09 · 10-Q 2025-11-10 · 10-Q 2025-08-12 · 10-Q 2025-05-12 · 10-K 2025-03-05

Rated on July 29, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

4 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years 27.1%
  • More than 10% revenue growth is expected for the coming year -92.3%
  • Share count grows by less than 3% a year 8.9%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -383.9%
  • Gross margin at 40% or higher and without meaningful erosion 100.0%
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA 70 m net cash
  • Operating cash flow covers the profits of the last three years 43 m
  • Return on capital at 15% or higher, or up versus two years ago -70.8%
  • Insiders hold at least 10% or are net buyers 0.2%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

2/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% 23.5%
  • Exp. sales growth 3Y > 5% -30.8%
  • EBIT growth 10Y > 5%
  • Exp. EBIT growth 3Y > 5% -30.8%
  • Net debt < 4x EBIT
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50%
  • Return on equity > 15% -586.6%
  • ROCE > 15% -70.8%
  • Expected return > 10% -58.5%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Sep 3, 2026 Parison Amy SVP, Chief Financial Officer Sell 453 3.04 1,376
Sep 3, 2026 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Sell 709 3.04 2,153
Sep 3, 2026 O'Neill Gilmore Neil CEO Sell 5,124 3.04 15,563
Aug 3, 2026 Parison Amy SVP, Chief Financial Officer Sell 678 2.58 1,749
Jul 28, 2026 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER Sell 4,928 2.67 13,158

View all insider transactions →

The company

About the Company

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Employees
87
Headquarters
Cambridge, MA
Address
11 Hurley Street, 02141 Cambridge, United States
Phone
617 401 9000
IPO Date
02/03/2016
ISIN
US28106W1036

Management

Management
Name Title Birth Year
Gilmore O'Neill M.D. President, CEO & Director 1964
Amy Parison Senior VP & CFO 1986
Linda C. Burkly Ph.D. Executive VP & Chief Scientific Officer 1957
Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member
George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member 1954
Gregory Whitehead Executive VP and Chief Technical & Quality Officer
Damien Grierson J.D. Senior VP, General Counsel & Corporate Secretary
Tom Love Vice President of People
Frank Panaccio Senior VP & Chief Business Officer
Brieana Buckley Senior Vice President of Development and Program Leadership

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Filings

Company Filings (8-K)

An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).

  • 08/05/2026 Editas Medicine, Inc. (EDIT): Results of Operations and Financial Condition; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?